Uncategorized
Imprimis enters licensing agreement for dry eye formulation
Imprimis Pharmaceuticals has obtained exclusive licensing rights to Klarity, a topical treatment for dry eye disease, according to a company press release.Klarity, developed by OSN Chief Medical Editor Richard L. Lindstrom, MD, is a patented ophthalmic topical solution and gel technology designed to treat ocular surface pathology associated with ophthalmic surgery, contact lens wear or patients with moderate to severe dry eye, the release said.